View text source at Wikipedia
Clinical data | |
---|---|
Trade names | Mexidol |
Other names | Emoxipine, Emoxypin, Epigid, 6-Methyl-2-ethyl-3-hydroxypyridine |
Routes of administration | Oral & IV |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Elimination half-life | 2-2.6 h |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.205.098 |
Chemical and physical data | |
Formula | C8H11NO |
Molar mass | 137.182 g·mol−1 |
3D model (JSmol) | |
Melting point | 170 to 172 °C (338 to 342 °F) [1] |
| |
| |
(verify) |
Emoxypine (2-ethyl-6-methyl-3-hydroxypyridine), also known as Mexidol or Mexifin, a succinate salt, is chemical compound which is claimed by its manufacturer, the Russian company Pharmasoft Pharmaceuticals, to have antioxidant and actoprotector properties,[2][3] but these purported properties of emoxypine have not been proven.[4] Its chemical structure resembles that of pyridoxine (a type of vitamin B6).
Emoxypine was first synthesized by L.D. Smirnov and K.M. Dumayev, then studied and developed in the Russian Institute of Pharmacology, Russian Academy of Medical Sciences and Russian Scientific Center of Bioactive Substances Safety.[5] Its research and use has been largely isolated to former soviet states, with little interest from other countries.[6]
Emoxypine is widely used in Russia, primarily for its anti-oxidant properties claimed by the manufacturer. It purportedly exercises anxiolytic,[7][8] anti-stress, anti-alcohol, anticonvulsant, nootropic, neuroprotective and anti-inflammatory action.[citation needed] Emoxypine presumably improves cerebral blood circulation, inhibits thrombocyte aggregation, lowers cholesterol levels, has cardioprotective and antiatherosclerotic action.[5] Compound's iron chelating property in vitro, shows potential in the management of neurodegenerative conditions such as Alzheimer's disease (AD), as well as hematologic disorders.[6]
Emoxypine's purported mechanism of action is believed to be its antioxidant and membrane-protective effects with the following key components:[5][9][medical citation needed] Still, the antioxidant and membrane-protective effects have not been proved in reviews and meta-analysis[4][medical citation needed] The purported actions of emoxypine are:
One non-blinded non-randomized study determined the effectiveness of emoxypine in 205 patients with clinical manifestations of lumbosacral radiculopathy (LSR). Patients were divided into two groups, and further were divided into subgroups depending on the presence of motor disturbances. All patients received a course of conventional medical treatment and physiotherapy; main group additionally received emoxypine. Thereafter, clinical-neurological control of long-term results of treatment in subgroups of patients was performed. The results showed that the use of emoxypine in the combined therapy of patients with LSR led to significant and persistent reduction of severity of pain syndrome and rapid recovery of function of spinal roots and peripheral nerves compared with conventional therapy.[5][4] Still, these studies were primary research not confirmed in reviews and meta-analysis.[11] Based on the available information,[4] it can be concluded that the effectiveness or purported pharmaceutical efficiency of emoxypine has not been confirmed through comprehensive reviews or meta-analyses. Most of the studies on emoxypine are primary research and have not been validated in systematic reviews or meta-analyses.[4]
Emoxypine is an uncontrolled substance in the United States meaning it is legal to possess without a license or prescription.